The Optimal Duration of Pertuzumab Treatment for Patients With HER2+ Breast Cancer

September 19, 2017
Gunter von Minckwitz, MD, PhD

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses questions still surrounding the optimal duration of pertuzumab (Perjeta) treatment for patients with HER2-positive breast cancer.